Health TrialsbyHealthPanel

SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)

ConditionsRectal AdenocarcinomaHigh-Risk CancerMSS
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSixth Affiliated Hospital, Sun Yat-sen University

About this trial

To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level evidence-based medical evidence for the use in the treatment of high-risk rectal cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Before conducting procedures related to the research protocol but not part of routine care, written informed consent, voluntarily signed and dated by the subject, must be obtained in accordance with regulations and institutional guidelines.

Age 18-75 years.

Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma; all other histological types are excluded.

Distance from the lower margin of the rectal tumor to the anal verge ≤10 cm.

Disqualifiers

Patients with a history of severe drug allergies (including allergies to platinum agents, 5-FU, LV, and 5-HT3 receptor antagonists);

Patients who have participated in or are currently participating in other clinical trials within 4 weeks prior to enrollment;

A history of having received anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapy;

Severe electrolyte abnormalities;

Trial design

Design model

Single group

Treatments tested in this trial

  • Short-Course Radiotherapy

    Radiation

    Patients undergo SCRT at a dose of 5Gy × 5 fractions

  • PD-1 monoclonal antibody

    Drug

    Patients complete immune therapy with PD-1 monoclonal antibody for 4 cycles.

  • mFOLFOX6 regimen

    Drug

    Patients complete chemotherapy with mFOLFOX6 regimen for 4 cycles.

  • Cetuximab

    Drug

    Patients with RAS/BRAF wild-type receive targeting therapy with Cetuximab for 4 cycles.

  • Bevacizumab

    Drug

    Patients with RAS/BRAF mutations receive targeting therapy with Bevacizumab for 3 cycles. (Bevacizumab is not used in the last cycle of the bevacizumab group)

  • Surgical resection

    Procedure/Surgery

    Surgery either local excition or total mesorectal excision is performed 8-10 weeks after the completion of short-course radiotherapy.

Treatment groups

49 Participants
are divided into 1 treatment group
Group A: SCRT + mFOLFOX6 + PD-1 Antibody + Targeted TherapyExperimental treatment 6 interventions

Trial outcomes

Primary outcomes

1

Pathological Complete Response

Pathological Complete Response

Time frame
1 year

Secondary outcomes

1

3 Year Disease Free Survival

3 Year Disease Free Survival

Time frame
3 years
2

3 Year Overall Survival

3 Year Overall Survival

Time frame
3 years
3

3 Year Local Relapse Free Survival

3 Year Local Relapse Free Survival

Time frame
3 years
4

R0 resection rate

R0 resection rate

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sixth Affiliated Hospital, Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov
Apply now